Research on the Development and Joint Improvement of Ceramsite Lightweight High-Titanium Heavy Slag Concrete Precast Composite Slab

Despite the continuous improvement in the research and development of concrete precast composite slab technology, problems like easy cracks and excessive weight at the joints remain. In this study, high-titanium heavy slag was mixed with different kinds of ceramsite to prepare ceramsite lightweight high-titanium heavy slag concrete. The joint of the composite slab was optimized to develop a novel ceramsite lightweight high-titanium heavy slag concrete precast composite slab, hereinafter referred to as “CLHCPCS”. Two CLHCPCS and one ordinary concrete composite slab were prepared. This study analyzed the effects of new materials and improved joints on the flexural capacity and crack resistance of CLHCPCS. It concluded that the density of high-titanium heavy slag concrete with shale ceramsite decreased by 12.0%, and the density of high-titanium heavy slag concrete with fly ash ceramsite decreased by 10.6%. At a 30% dosage of fly ash ceramsite, the compressive strength and splitting tensile strength of concrete reached the maximum. At a 20% dosage of shale ceramsite, the mechanical properties were optimal. Finally, fly ash ceramsite was selected as part coarse aggregate of CLHCPCS. CLHCPCS 1 and 2 demonstrated superior ultimate bearing capacity and crack resistance than ordinary concrete composite slab DBS1, with its ultimate bending capacity test value higher than the average value of ordinary concrete composite slab. ANSYS established the joint model of CLHCPCS for a bending simulation test. The stress and strain distribution of the model and the ultimate bending capacity under the plastic line method were obtained, consistent with theory and experimental analysis results

Does the Artificial Enhancement and Release Activity Affect the Genetic Diversity of Marbled Rockfish <i>Sebastiscus marmoratus</i> in Zhoushan Waters?

Artificial enhancement and release activity is an important method in the restoration of fishery resources. In order to understand the possible genetic effect of hatchery-released populations on wild populations during the artificial enhancement and release activities of Sebastiscus marmoratus in Zhoushan waters, we utilized mitochondrial DNA control region sequences to examine the genetic diversity in four S. marmoratus populations, including one farmed population, one released population and two wild populations. A total of 68 haplotypes from 123 individuals were detected, including 3 shared haplotypes. Haplotype diversity ranged from 0.944 to 0.980, with a mean of 0.966. The nucleotide diversity ranged from 0.020 to 0.025, with a mean of 0.022. Analysis of Molecular Variance (AMOVA) indicated that the primary genetic variation occurs within populations and the index of genetic differentiation between populations (FST) among the four populations showed no differentiation. The results indicate that the current artificial enhancement and release has not impacted the S. marmoratus population in Zhoushan waters. Continued long-term monitoring is essential to protect the high-quality germplasm resources of S. marmoratus

Melt extrusion deposition (MED™) 3D printing technology – A paradigm shift in design and development of modified release drug products

Three-dimensional printing (3DP) technology offers unique advantages for pharmaceutical applications. However, most of current 3D printing methods and instrumentations are not specifically designed and developed for pharmaceutical applications. To meet the needs in pharmaceutical applications for precision, compatibility with a wide range of pharmaceutical excipients and drug materials without additional processing, high throughput and GMP compliance, an extrusion-based 3D printer based on Melt Extrusion Deposition (MED™) 3D printing technology was developed in this study. This technology can process powder pharmaceutical excipients and drugs directly without the need of preparing filament as required by FDM 3D printing. Six different tablet designs based on compartment models were used to demonstrate the precision and reproducibility of this technology. The designed tablets were fabricated using the GMP-compliant MED™ 3D printer and were evaluated in vitro for drug release and in vivo for selected designs using male beagle dogs. Tablet designs with one or more compartments showed versatile release characteristics in modulating the release onset time, release kinetics, duration of release and mode of release. Multiple drugs or formulations were fabricated into a single tablet to achieve independent release kinetics for each drug or to fine-tune the pharmacokinetic profile of a drug. Building upon the theoretical analysis of models, precision and reproducibility of MED™ 3D printing technology, a novel product development approach, 3D printing formulation by design (3DPFbD®) was developed to provide an efficient tool for fast and efficient pharmaceutical product development. The MED™ 3D printing represents a novel and promising technology platform encompassing design and development of modified drug release products and has potential to impact the drug delivery and pharmaceutical product development